Eir Ventures

Moleculent is a biotechnology company focused on advancing human health through the development of technology-enabled products that harness insights from the molecular foundations of human biology. By decoding human biology, the company aims to enhance therapies and diagnostics, thereby improving healthcare outcomes. Moleculent anticipates significant advancements in the understanding of molecular biology over the next decade, which will facilitate the creation of innovative treatments and diagnostic tools. Their mission centers on providing healthcare professionals with access to molecular science-based solutions that address various health challenges.

ArgusEye is a biotechnology company specializing in sensor solutions for real-time detection of biological systems and processes. The company utilizes patented nanoplasmonic sensing technology integrated with fiber optics, enabling the creation of highly sensitive and flexible sensing systems. By incorporating customized receptors, ArgusEye can tailor its technology to detect a wide range of biological targets, making it applicable across various fields. This innovative approach is grounded in extensive academic research, positioning ArgusEye at the forefront of advancements in biosensing technology.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective, safe, and disease-modifying treatment options. Hoba Therapeutics aims to offer relief and prevention for chronic pain and hearing loss, addressing significant medical needs for patients suffering from these conditions.

Henlez is a biotechnology company focused on developing enzyme-based therapies for recurrent follicular skin disorders. The company utilizes precise enzymes to formulate effective topical treatments aimed at managing conditions such as hidradenitis. Henlez's technology is designed to produce potent and stable enzymes that are safe, effective, and affordable for patients. Through its innovative approach, Henlez addresses a significant need in dermatological care, providing patients with reliable options for managing their skin conditions. The company is accessible for inquiries via mail, phone, or in-person visits.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.

Synklino is focused on developing a CMV-specific immunotoxin aimed at eradicating cytomegalovirus (CMV) infections. This innovative immunotoxin is designed to be highly effective, potent, and fast-acting, targeting both lytically and latently infected cells. By providing rapid relief from CMV, Synklino aims to improve the long-term survival of transplant recipients, ultimately enhancing their overall health and quality of life. The company's approach promises to deliver significant benefits for patients undergoing transplantation by addressing the challenges posed by CMV infections.

Cinclus Pharma AG is a clinical-stage biotechnology company based in Basel, Switzerland, specializing in the development of small molecules for the treatment of gastric acid-related diseases, particularly gastroesophageal reflux disease (GERD). The company's lead asset, X842, is designed for patients suffering from severe erosive GERD, a condition for which effective treatment options are limited. In addition to X842, Cinclus Pharma is exploring a dual therapy approach that combines an antibiotic targeting Helicobacter pylori, a bacterium associated with gastric and duodenal mucosal issues. The company's research efforts aim to address significant unmet medical needs in the treatment of these conditions.

Scenic Biotech is a biotechnology company focused on developing innovative genomics and immunotherapy technologies aimed at addressing severe diseases, including cancer and rare genetic disorders. The company's approach involves identifying genetic suppressors, which are genes that can counteract the effects of disease-causing mutations, thus serving as new drug targets. By leveraging its advanced technology, Scenic Biotech enables scientists to rapidly identify and validate these novel drug targets, facilitating the development of disease-modifying therapeutics. This targeted strategy not only enhances the understanding of genetic influences on diseases but also aims to improve treatment outcomes for affected patients.

Strike Pharma specializes in personalized cancer treatment through its proprietary Adaptable Drug Affinity Conjugate (ADAC) technology. The company employs an antibody-based approach tailored to the genetic profile of each patient's tumor, effectively targeting and destroying cancer cells while sparing healthy cells. This method not only aims to enhance the efficacy of treatment but also strives to reduce the risk of side effects, making it a more affordable option for patients. By focusing on scalable personalized immunotherapy, Strike Pharma seeks to improve outcomes for individuals facing cancer.

Synklino is focused on developing a CMV-specific immunotoxin aimed at eradicating cytomegalovirus (CMV) infections. This innovative immunotoxin is designed to be highly effective, potent, and fast-acting, targeting both lytically and latently infected cells. By providing rapid relief from CMV, Synklino aims to improve the long-term survival of transplant recipients, ultimately enhancing their overall health and quality of life. The company's approach promises to deliver significant benefits for patients undergoing transplantation by addressing the challenges posed by CMV infections.